| Field | Specification |
|---|---|
| Mfr No | |
| Alternative Names | alpha catenin antibody; alpha E catenin antibody; Alpha E-catenin antibody; alphaE catenin antibody; Cadherin associated protein 102kDa antibody; Cadherin associated protein antibody; Cadherin-associated protein antibody; CAP 102 antibody; CAP102 antibody; Catenin (cadherin associated protein) alpha 1 102kDa antibody; Catenin (cadherin associated protein), alpha 1, 102kDa antibody; Catenin alpha 1 antibody; Catenin alpha-1 antibody; CTNA1_HUMAN antibody; CTNNA 1 antibody; CTNNA1 antibody; FLJ36832 antibody; FLJ52416 antibody; NY REN 13 antigen antibody; OTTHUMP00000224141 antibody; OTTHUMP00000224147 antibody; Renal carcinoma antigen NY REN 13 antibody; Renal carcinoma antigen NY-REN-13 antibody |
| Cellular Localization | |
| Clonality | |
| Concentration | |
| Host | |
| Immunogen | E.coli-derived human CTNNA1 recombinant protein (Position: D143-D292). Human CTNNA1 shares 98% amino acid (aa) sequence identity with mouse CTNNA1. |
| Isotype | |
| Molecular Weight | |
| Product Type | |
| Reactivity | |
| Reconstitution | |
| Target | |
| UniProt # |
Overview
Anti-alpha 1 Catenin/CTNNA1 Antibody Picoband® (monoclonal, 10I2) is an antibody for CTNNA1 detection raised in Mouse (Monoclonal, clone Clone: 10I2, Mouse IgG1), with reported reactivity: Human,Mouse,Rat. Commonly used in WB, IHC, Flow Cytometry, ELISA workflows.
Key elements and design rationale
- Target: CTNNA1 (catenin (cadherin-associated protein), alpha 1, 102kDa); UniProt: P35221
- Antibody format: Mouse, Monoclonal, clone Clone: 10I2, Mouse IgG1
- Molecular weight: 100 kDa
- Applications: WB, IHC, Flow Cytometry, ELISA
Vendor description (summary): Boster Bio Anti-alpha 1 Catenin/CTNNA1 Antibody Picoband® (monoclonal, 10I2) catalog # M01617-1.
Biological background
Biological context: Associates with the cytoplasmic domain of a variety of cadherins. The association of catenins to cadherins produces a complex which is linked to the actin filament network, and which seems to be of primary importance for cadherins cell-adhesion properties. Can associate with both E- and N-cadherins. Originally believed to be a stable component of E-cadherin/catenin adhesion complexes and to mediate the linkage of cadherins to the actin cytoskeleton at adherens junctions. In contrast, cortical actin was found to be much more dynamic than E-cadherin/catenin complexes and CTNNA1 was shown not to bind to F-actin when assembled in the complex suggesting a different linkage between actin and adherens junctions components. The homodimeric form may regulate actin filament assembly and inhibit actin branching by competing with the Arp2/3 complex for binding to actin filaments. May play a crucial role in cell differentiation.
Expression and localization notes: cellular localization: Cytoskeleton. Cell membrane. Peripheral membrane protein. Cytoplasmic side. Adherens junction. Cell junction., tissue context: Expressed ubiquitously in normal tissues..
Common research applications
- Western blotting (WB): Compare CTNNA1 levels across samples and conditions using appropriate loading and biological controls.
- Immunohistochemistry (IHC): Evaluate spatial distribution of CTNNA1 in tissue sections, considering fixation and antigen retrieval effects.
- Flow cytometry: Quantify CTNNA1-positive populations in single-cell suspensions with appropriate gating and controls.
- ELISA: Use antibody-based detection formats to assess antigen presence or binding in plate-based assays.
Notes for experimental interpretation
- Account for isoforms, post-translational modifications, and sample-specific processing that can shift apparent molecular weight or epitope accessibility.
- Use positive/negative biological controls where possible (e.g., known-expressing cells/tissues, knockdown/knockout models) and include appropriate secondary-only/isotype controls for imaging workflows.
Additional product notes (from provided fields)
- Specificity: No cross reactivity with other proteins.
- Background: CTNNA1, also known as Catenin alpha-1 or Catenin (cadherin-associated protein), alpha 1, is a protein that in humans is encoded by the CTNNA1 gene. It is mapped to 5q31.2. When surface epithelium CTNNA1 was ablated, hair follicle development was blocked and epidermal morphogenesis was dramatically affected, with defects in adherens junction formation, intercellular adhesion, and epithelial polarity. In vitro, CTNNA1 null keratinocytes were poorly contact inhibited and grew rapidly. These differences were not dependent upon intercellular adhesion and were in marked contrast to keratinocytes conditionally null for another essential intercellular adhesion protein, desmoplakin Knockout keratinocytes exhibited sustained activation of the Ras-MAPK cascade due to aberrations in growth factor responses. It is concluded that features of precancerous lesions often attributed to defects in cell cycle regulatory genes can be generated by compromising the function of CTNNA1.
- Cross reactivity: No cross-reactivity with other proteins.
- Cellular localization: Cytoskeleton. Cell membrane. Peripheral membrane protein. Cytoplasmic side. Adherens junction. Cell junction.
- Tissue details: Expressed ubiquitously in normal tissues.
- Research category: Actin Binding Proteins,Actin, etc.,Cytoskeleton,Cytoskeleton/ECM,Microfilaments,Signal Transduction
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.